治疗类风湿关节炎的新靶点研究进展  

Novel therapeutic targets for the treatment of rheumatoid arthritis

作　　者：苏有瑞 嵇莹莹 龚国清[1] 

机构地区：[1]中国药科大学药学院,南京211198

出　　处：《中国新药杂志》2017年第17期2019-2025,共7页Chinese Journal of New Drugs

基　　金：国家"重大新药创制"科技重大专项资助项目(6100010053A)

摘　　要：类风湿关节炎(RA)是一种能够导致关节滑膜炎症和破坏的自身免疫性疾病。尽管已发现了众多治疗这种异质性疾病的药物,但仍有30%的患者的疾病不能得到很好控制。因此,寻找新的治疗靶点,开发新的治疗药物显得尤为重要。本文对在类风湿关节炎领域被认为是很有趣的新型治疗靶点的2条通路JAK激酶通路和T辅助细胞17通路进行讨论。同时,也对生物制剂的治疗潜力和阻断这些途径的小分子抑制剂进行了综述。Rheumatoid arthritis（ RA） is an autoimmune disease that leads to inflammation and destruction of synovial joints. Although many drugs for this heterogeneous disease have been discovered,30% of patients still cannot be well controlled. Therefore,it is particularly important to find new therapeutic targets and develop new therapeutic drugs. Two pathways,named the Janus kinase（ JAK） pathway and the T helper-17（ Th17） pathway,which are regarded as interesting novel therapeutic targets in the field of rheumatology,are discussed. The treatment potential of biologicals and the small-molecule inhibitors that can block these pathways are also reviewed in this paper.

关 键 词：类风湿关节炎 JAK-STAT途径 IL-17-Th17途径 生物制剂 小分子抑制剂 

分 类 号：R917[医药卫生—药物分析学]